Bristol-Myers Squibb to buy Inhibitex for $2.5 billion

Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).

The transaction has been approved by the boards of directors of both companies, the Saturday announcement said.

Inhibitex has been focusing on development of nucleotide medicines designed for treatment of hepatitis C.

Its lead product under development, known as INX-189, has displayed potent antiviral abilities, experts said.

"The acquisition of Inhibitex builds on Bristol-Myers Squibb's long history of discovering, developing and delivering innovative in virology and enriches our portfolio of investigational medicines for hepatitis C," Lamberto Andreotti, of Bristol-Myers Squibb, said in a statement.

"There is significant unmet medical need in ," he added. "This acquisition represents an important investment in the long-term growth of the company."

Russell Plumb, president and CEO of Inhibitex, said the transaction puts INX-189 and his company's other assets in the hands of an organization that can "more optimally develop them."

Bristol-Myers Squibb will finance the acquisition, which is expected to be completed in about a month, from its existing cash resources, officials said.

add to favorites email to friend print save as pdf

Related Stories

Initial Hepatitis C drug trial complete

Sep 02, 2010

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

Trials begin on potent new hepatitis C drug

May 14, 2010

The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

Bristol-Myers Squibb sees 3Q profit dip 2 percent

Oct 26, 2010

(AP) -- Bristol-Myers Squibb Co. posted a slight decline in third-quarter profit Tuesday as its restrained spending was offset by flat sales of its drugs, lower income from its partners and bigger discounts to government ...

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.